IFIH1 and myositis disease: These entities are often characterized by the production of specific autoantibodies targeting nuclear or cytoplasmic antigens, known as myositis-specific autoantibodies, including anti-Mi-2 helicase (anti-Mi-2), anti-small ubiquitin-like modifier activating enzyme (anti-SAE), anti-melanoma differentiation-associated gene 5 (anti-MDA5), autoantibodies against aminoacyl-tRNA synthetases (anti-ARS), anti-nuclear matrix protein 2 (anti-NXP2), anti-TIF1γ, anti-histidyl-tRNA synthetase (anti-Jo-1) antibodies, among others [1].